Carisma Therapeutics (CARM) Institutional Ownership $0.19 0.00 (-0.26%) Closing price 04:00 PM EasternExtended Trading$0.20 +0.00 (+1.77%) As of 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Carisma Therapeutics (NASDAQ:CARM)CurrentInstitutional OwnershipPercentage44.27%Number ofInstitutional Buyers(last 12 months)5TotalInstitutional Inflows(last 12 months)$1.21MNumber ofInstitutional Sellers(last 12 months)5TotalInstitutional Outflows(last 12 months)$1.14M Get CARM Insider Trade Alerts Want to know when executives and insiders are buying or selling Carisma Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data CARM Institutional Buying and Selling by Quarter Remove Ads Carisma Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/17/2025Millennium Management LLC120,157$50K0.0%-15.7%0.288% 2/13/2025Renaissance Technologies LLC231,357$97K0.0%+11.9%0.554% 11/19/2024Barclays PLC549,305$539K0.0%+3,661,933.3%1.316% 11/16/2024Geode Capital Management LLC259,184$254K0.0%-8.5%0.621% 11/15/2024Barclays PLC549,305$539K0.0%+3,661,933.3%1.316% 11/15/2024Wexford Capital LP34,861$34K0.0%+75.5%0.083% 9/16/2024Point72 Asia Singapore Pte. Ltd.26,006$40K0.0%N/A0.063% 8/15/2024Point72 Asia Singapore Pte. Ltd.26,006$40K0.0%N/A0.063% 8/15/2024TPG GP A LLC842,031$1.28M0.0%-42.0%2.027% 8/9/2024Renaissance Technologies LLC139,360$212K0.0%-38.3%0.335% Get the Latest News and Ratings for CARM and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Carisma Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 5/10/2024Vanguard Group Inc.1,579,961$3.59M0.0%+0.7%3.803% 5/7/2024Empowered Funds LLC26,984$61K0.0%-43.9%0.065% 2/14/2024Trustees of The University of Pennsylvania1,252,107$3.67M10.3%-28.9%3.102% 10/13/2023SG Americas Securities LLC13,653$58K0.0%N/A0.034% 9/21/2023Barclays PLC5,312$47K0.0%N/A0.013% 8/4/2023American International Group Inc.12,834$113K0.0%N/A0.032% 7/27/2023EA Series Trust40,434$355K0.0%N/A0.100% 6/15/2023Trustees of The University of Pennsylvania2,182,812$6.77M6.6%N/A5.422% 5/15/2023Wittenberg Investment Management Inc.46,703$145K0.1%N/A0.459% 5/12/2023Deuterium Capital Management LLC51,256$159K0.2%N/A0.504% 5/10/2023Connor Clark & Lunn Investment Management Ltd.14,796$46K0.0%N/A0.145% 5/3/2023Jump Financial LLC17,542$54K0.0%N/A0.172% 5/1/2023Virtu Financial LLC15,335$48K0.0%N/A0.151% 4/27/2023Stratos Wealth Partners LTD.19,899$62K0.0%N/A0.195% 4/24/2023Blodgett Wealth Advisors LLC29,660$92K0.1%N/A0.291% 4/14/2023BML Capital Management LLC411,398$1.28M1.1%N/A4.041% (Data available from 1/1/2016 forward)Remove Ads CARM Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of CARM shares? During the previous two years, 21 institutional investors and hedge funds held shares of Carisma Therapeutics. The most heavily invested institutionals were Trustees of The University of Pennsylvania ($3.67M), Vanguard Group Inc. ($3.59M), TPG GP A LLC ($1.28M), BML Capital Management LLC ($1.28M), Barclays PLC ($539K), EA Series Trust ($355K), and Geode Capital Management LLC ($254K).Learn more on CARM's institutional investors. What percentage of Carisma Therapeutics stock is owned by institutional investors? 44.27% of Carisma Therapeutics stock is owned by institutional investors. Learn more on CARM's institutional investor holdings. Which institutional investors have been buying Carisma Therapeutics stock? Of the 17 institutional investors that purchased Carisma Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Trustees of The University of Pennsylvania ($2.18M), Barclays PLC ($1.10M), BML Capital Management LLC ($411.40K), Point72 Asia Singapore Pte. Ltd. ($52.01K), Deuterium Capital Management LLC ($51.26K), Wittenberg Investment Management Inc. ($46.70K), and EA Series Trust ($40.43K). How much institutional buying is happening at Carisma Therapeutics? Institutional investors have bought a total of 4,063,026 shares in the last 24 months. This purchase volume represents approximately $10.43M in transactions. Which Carisma Therapeutics major shareholders have been selling company stock? The following institutional investors have sold Carisma Therapeutics stock in the last 24 months: TPG GP A LLC ($609.85K), Trustees of The University of Pennsylvania ($507.74K), Renaissance Technologies LLC ($86.64K), Geode Capital Management LLC ($24.22K), Millennium Management LLC ($22.37K), and Empowered Funds LLC ($21.15K). How much institutional selling is happening at Carisma Therapeutics? Institutional investors have sold a total of 1,271,961 shares in the last 24 months. This volume of shares sold represents approximately $2.63M in transactions. Related Companies InterCure Major Shareholders Cue Biopharma Major Shareholders Applied Therapeutics Major Shareholders Anebulo Pharmaceuticals Major Shareholders PMV Pharmaceuticals Major Shareholders Sutro Biopharma Major Shareholders Inozyme Pharma Major Shareholders Metagenomi Major Shareholders Quince Therapeutics Major Shareholders Gain Therapeutics Major Shareholders This page (NASDAQ:CARM) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredWall St. Icon: Looming Financial Tsunami Could Wipe Out the 1%Wall Street icon who forecasted Black Monday and dot-com crash says a new economic event could hit the America...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Carisma Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Carisma Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CARM Stock Free CARM Stock Alerts